

Tdap Vaccine

Age Group	Dose	Route	# of Doses	Storage & Handling
10-64 years Recommended Off-Label Use of Tdap Selected 7-9 year olds* 65 years and older if close contact to an infant‡	0.5 mL	IM (Intramuscularly)	Single lifetime dose	Keep vaccine refrigerated between 35°- 46° F DO NOT FREEZE

* Boostrix® is licensed in the U.S. for children aged 10 years and over, however Adacel® is licensed for children starting at age 11 years. Either vaccine may be used to vaccinate children 7-10 years or adults 65 years and older when indicated.

Tdap Vaccine Recommendations

ACIP Recommendations

- Routine vaccination is recommended for all adolescents aged 11 through 18 years who have completed the recommended childhood diphtheria, tetanus toxoids and pertussis (DTP/DTaP) vaccination series. Adolescents should preferably receive Tdap at the 11 to 12 year-old preadolescent healthcare visit.
- Adults aged 19 through 64 years not previously vaccinated with Tdap should receive a single dose of Tdap.
- Adults aged 65 years and older not previously vaccinated with Tdap who have or anticipate having close contact with an infant less than 12 months of age should be vaccinated with a single dose of Tdap. Other adults ages 65 years and older may be vaccinated as well.‡
- Children aged 7 through 10 years who are not fully vaccinated against pertussis (fewer than 4 doses or have had 4 doses of DTaP and last dose was prior to age 4 years) and do not have a contraindication to pertussis vaccine should receive a single dose of Tdap.*

Timing of Tdap

- Tdap can be administered at any time **regardless** of interval since the last tetanus- or diphtheria-toxoid containing vaccine.
- Persons, including pregnant women, who were never vaccinated against tetanus, diphtheria, or pertussis or who have unknown vaccination status should receive a series of three vaccinations containing tetanus and diphtheria toxoids. The first of these three doses should be Tdap followed by a dose of Td 4 weeks later. The last dose should be another Td at least 6 months after the Td dose.



Tdap for Persons without a History of DTaP or DTP

Persons without documentation of having a series of DTaP/DTP/DT/Td should receive 3 vaccinations:

- Single dose of Tdap
- Td 4 weeks (28 days) after Tdap
- 2nd dose of Td at least 6 months after Td dose

AB 354 School Law

- Beginning July 1, 2012 and beyond, all students entering 7th grade will need proof of a Tdap booster before starting school. This new school law applies to all public and private schools in California.
- For additional information, resources, and forms please go to www.shotsforschool.org.

For more information on Tdap or any of the recommended vaccines, visit the Immunization Program website at <http://publichealth.lacounty.gov/ip/providers/B71.htm> or call (213) 351-7800.

Tdap Vaccine

Priority Groups

Women of Childbearing Age/Pregnant Women

- All women of childbearing age should receive a single dose of Tdap if they have not been previously vaccinated.
- All pregnant women and adolescents who have not previously received Tdap should receive Tdap preferably in the third or late second trimester (after 20 weeks gestation). Alternatively, Tdap can be administered immediately in the postpartum period.
- Pregnant women should be advised that there is limited data on the safety, immunogenicity, and outcomes of pregnancy in pregnant women who receive Tdap. Also, it is unknown if Tdap given in pregnancy will interfere with the infant's immune response to vaccination.
- Pregnant women due for a tetanus booster should receive Tdap if they have not been previously been vaccinated. The vaccine should be administered during the third or late second (after 20 weeks gestation) trimester.
- Women of childbearing age and pregnant women with unknown or incomplete tetanus vaccination status should receive three vaccinations containing tetanus and reduced diphtheria toxoids at 0, 4 weeks, and 6-12 months. Tdap should replace 1 dose of Td. Tdap should be administered to pregnant women after 20 weeks gestation.

Close Contacts of Infants

- All close contacts of infants (age 10 years and older including persons 65 years and older) without documentation of Tdap, especially parents, siblings, and childcare providers, should be immunized before the mother and baby are discharged after birth, regardless of when the contacts received any prior doses of Td. Ideally close contacts should be vaccinated 2 weeks before beginning close contact with the infant.

Health Care Personnel

- All health care personnel (HCP), particularly those who have direct contact with infants and pregnant women should receive Tdap to protect their patients and themselves, regardless of their age and time since last Td. HCP without direct patient contact should be vaccinated as well.

Patients with Wounds

- Administer Tdap once (instead of Td or TT) if tetanus toxoid is indicated for wound management in patients 7 years of age and older, including person 65 and older.

Contraindications

- Severe allergic reaction to a vaccine component or following a prior dose of vaccine.
- Encephalopathy not due to another identifiable cause occurring within 7 days after vaccination with a pertussis-containing vaccine.

Precautions

- History of Guillain-Barre syndrome within 6 weeks after a previous dose of tetanus toxoid-containing vaccine.
- Progressive neurologic disorder until the condition has stabilized.
- History of a severe local reaction (arthrus) following a prior dose of a tetanus and/or diphtheria toxoid-containing vaccine.
- Moderate or severe acute illness.
- Latex allergy for Boostrix supplied in pre-filled syringes (do not use if there is a history of a severe [anaphylactic] allergy to latex; can use if less severe allergies). Boostrix single dose vials and Adacel do not contain latex.
- Acute moderate or severe illness with or without fever.

Adverse Reactions

- Local reactions (pain, redness, swelling).
- Temp of 100.4°F or higher.
- Adverse reactions occur at approximately the same rate as Td alone (without acellular pertussis vaccine).
- Rarely, anaphylaxis or generalized urticaria have been reported after tetanus toxoid administration.

